JP2000505650A - 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物 - Google Patents

樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物

Info

Publication number
JP2000505650A
JP2000505650A JP9528715A JP52871597A JP2000505650A JP 2000505650 A JP2000505650 A JP 2000505650A JP 9528715 A JP9528715 A JP 9528715A JP 52871597 A JP52871597 A JP 52871597A JP 2000505650 A JP2000505650 A JP 2000505650A
Authority
JP
Japan
Prior art keywords
cells
cell
dendritic
recombinant
dendritic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9528715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000505650A5 (enExample
Inventor
ヒュー，パトリック
リーブス，マーク
エー． ローゼンバーグ，スティーブン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2000505650A publication Critical patent/JP2000505650A/ja
Publication of JP2000505650A5 publication Critical patent/JP2000505650A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP9528715A 1996-02-08 1997-02-07 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物 Ceased JP2000505650A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1143396P 1996-02-08 1996-02-08
US60/011,433 1996-02-08
PCT/US1997/002063 WO1997029183A2 (en) 1996-02-08 1997-02-07 Methods and compositions for transforming dendritic cells and activating t cells

Publications (2)

Publication Number Publication Date
JP2000505650A true JP2000505650A (ja) 2000-05-16
JP2000505650A5 JP2000505650A5 (enExample) 2004-11-18

Family

ID=21750351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9528715A Ceased JP2000505650A (ja) 1996-02-08 1997-02-07 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物

Country Status (7)

Country Link
EP (1) EP0879281B1 (enExample)
JP (1) JP2000505650A (enExample)
AT (1) ATE314462T1 (enExample)
AU (1) AU730537B2 (enExample)
CA (1) CA2245170A1 (enExample)
DE (1) DE69734974D1 (enExample)
WO (1) WO1997029183A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529080A (ja) * 2008-07-24 2011-12-01 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 癌幹細胞を標的とする治療法
JP2013535209A (ja) * 2010-08-06 2013-09-12 ルードヴィヒ−マクシミリアン−ウニヴェルズィテート ミュンヘン Ｔ細胞の標的抗原の同定

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0840622A4 (en) * 1995-07-21 2003-01-02 Aventis Pharma Inc ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7351546B2 (en) 1998-09-22 2008-04-01 Becton, Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6495333B1 (en) 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
AU3755800A (en) * 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1046911A1 (en) * 1999-04-23 2000-10-25 Universiteit van Amsterdam Methods for identification of proteinaceous substances capable of inducing cellular reactions
WO2000073432A2 (en) * 1999-06-01 2000-12-07 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
FR2795415B1 (fr) 1999-06-28 2003-09-05 Roussy Inst Gustave Compose peptidique derive d'une orf decalee du gene ice
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
US7988963B1 (en) * 1999-10-15 2011-08-02 Baylor Research Institute Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7767202B2 (en) * 2001-03-16 2010-08-03 The Johns Hopkins University Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
FR2824567B1 (fr) 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
EP1450828B1 (en) 2001-08-17 2015-04-01 Roger Williams Hospital In situ immunization
US7955845B2 (en) 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2006249199A1 (en) 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
AU2013203832B2 (en) * 2012-03-13 2016-09-15 Celularity Inc. Modified erythrocyte precursor cells and uses thereof
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
EP0631618A4 (en) * 1992-03-04 1995-09-27 Systemix Inc CULTIVATION OF HEMOPOETIC STEM CELLS AND THEIR GENETOLOGICAL PRODUCTION.
EP0563485A1 (en) * 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
EP1624068A1 (en) * 1993-06-01 2006-02-08 Life Technologies Inc. Genetic immunization with cationic lipids
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
DK0765398T3 (da) * 1994-06-15 2003-09-29 Systemix Inc Population af celler, der er beriget for myeloide og/eller lymfoide progenitorer og fremgangsmåde til fremstilling og anvendelse deraf
EP0840622A4 (en) * 1995-07-21 2003-01-02 Aventis Pharma Inc ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529080A (ja) * 2008-07-24 2011-12-01 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 癌幹細胞を標的とする治療法
JP2013535209A (ja) * 2010-08-06 2013-09-12 ルードヴィヒ−マクシミリアン−ウニヴェルズィテート ミュンヘン Ｔ細胞の標的抗原の同定

Also Published As

Publication number Publication date
CA2245170A1 (en) 1997-08-14
AU2266097A (en) 1997-08-28
ATE314462T1 (de) 2006-01-15
DE69734974D1 (de) 2006-02-02
WO1997029183A2 (en) 1997-08-14
WO1997029183A3 (en) 1997-12-18
EP0879281B1 (en) 2005-12-28
AU730537B2 (en) 2001-03-08
EP0879281A2 (en) 1998-11-25

Similar Documents

Publication Publication Date Title
US7378277B2 (en) Methods and compositions for transforming dendritic cells and activating T cells
US6479286B1 (en) Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells
JP2000505650A (ja) 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
US11098284B2 (en) Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
US7670611B2 (en) Cancer immunotherapy with semi-allogeneic cells
US9095538B2 (en) Cancer vaccines and vaccination methods
EP2215220B1 (en) Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
US20010026937A1 (en) Monocyte-derived dendritic cell subsets
US20180085398A1 (en) Compositions and methods of treating cancer
Movassagh et al. High level of retrovirus-mediated gene transfer into dendritic cells derived from cord blood and mobilized peripheral blood CD34+ cells
Parajuli et al. Cytolysis of human dendritic cells by autologous lymphokine‐activated killer cells: participation of both T cells and NK cells in the killing
US7763251B2 (en) Kits to assess the risk of tumor progression
Banda et al. Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model
EP0995802B1 (en) Method for the delivery of nucleic acids to cells in vitro or ex vivo
JP2002522067A (ja) 一群の抗原を発現する操作された抗原提示細胞およびその使用
JP2002517409A (ja) 抗原提示細胞組成物の調製およびインビボ投与のための方法
US20100291683A1 (en) Modified Antigen Presenting Cells and Methods of Use
WO2001032841A9 (en) Method of in vitro t cell differentiation of cd34+ progenitor cells
AU2003220722A1 (en) Method for preparation and in vivo administration of antigen presenting cell composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080115

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080729